Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma
暂无分享,去创建一个
N. Damle | E. Boghaert | J. Dijoseph | Maureen M. Dougher | D. Armellino | P. Hamann | M. Dougher | J. Moran | Lyka B Kalyandrug | P. R. Hamann